Loading...
TransCode Therapeutics, Inc.
RNAZ•NASDAQ
Healthcare
Biotechnology
$11.74
$0.74(6.73%)
TransCode Therapeutics, Inc. (RNAZ) Financial Performance & Income Statement Overview
Review TransCode Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
19.35%
↑ 19.35%
Net Income Growth
9.66%
↑ 9.66%
Operating Cash Flow Growth
26.22%
↑ 26.22%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-470.15%
↓ 470.15%
ROIC
-0.12%
↓ 0.12%
TransCode Therapeutics, Inc. (RNAZ) Income Statement & Financial Overview
Review TransCode Therapeutics, Inc.'s (RNAZ) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | -$284482.00 | $142835.00 |
| Gross Profit | $0.00 | $0.00 | $284482.00 | -$142835.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $2.22B | $3.64M | $1.23M | $3.08M |
| SG&A Expenses | $951.65M | $1.45M | $938025.00 | $2.03M |
| Operating Expenses | $3.17B | $5.09M | $2.17M | $5.11M |
| Total Costs & Expenses | $0.00 | $5.09M | -$13.50M | $5.11M |
| Interest Income | $146000.00 | $159.00 | $179.00 | $178.00 |
| Interest Expense | -$114000.00 | $1832.00 | $10793.00 | $4482.00 |
| Depreciation & Amortization | $0.00 | $122855.00 | $127521.00 | $142834.00 |
| EBITDA | $0.00 | -$5.79M | -$21342.00 | -$5.04M |
| EBITDA Ratio | ||||
| Operating Income | $0.00 | -$5.09M | -$2.13M | -$5.11M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $0.00 | -$823570.00 | -$186577.00 | -$76898.00 |
| Income Before Tax | -$12.09B | -$5.92M | -$2.35M | -$5.19M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $179479.00 | $0.00 |
| Net Income | -$12.09B | -$5.92M | -$2.35M | -$5.19M |
| Net Income Ratio | ||||
| EPS | -$2505.62 | -$16.61 | $15.34 | -$24.42 |
| Diluted EPS | -$2505.62 | -$16.61 | $15.34 | -$24.42 |
| Weighted Avg Shares Outstanding | $4.82M | $356115.00 | $356115.00 | $213670.00 |
| Weighted Avg Shares Outstanding (Diluted) | $4.82M | $356115.00 | $356115.00 | $213670.00 |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan